Pacira BioSciences (PCRX) Operating Margin (2010 - 2026)
Pacira BioSciences (PCRX) recorded quarterly Operating Margin of 3.89% in Q1 2026, up 227.38% quarter-over-quarter from 1.19% in Q4 2025, and up 271.0% on a YoY basis from 1.05% in Q1 2025.
Pacira BioSciences (PCRX) Operating Margin (2010 - 2026) Analysis & Trends
Pacira BioSciences' Operating Margin history runs 17 years deep, the most recent figure standing at 3.89% for Q1 2026.
- In Q1 2026, Operating Margin rose 271.0% year-over-year to 3.89%; the TTM figure through Mar 2026 stood at 3.28% (up 1532.0% YoY), while the FY2025 annual figure was 2.64%, up 1311.0% from the prior year.
- Operating Margin was 3.89% for Q1 2026 at Pacira BioSciences, up from 1.19% in the prior quarter.
- In the past five years, Operating Margin ranged from a high of 23.53% in Q2 2023 to a low of 82.77% in Q3 2024.
- Historically, Operating Margin has averaged 3.74% across 5 years, with a median of 7.91% in 2024.
- The sharpest annual moves came in 2024 and 2025: Operating Margin tumbled 9358 bps in 2024, then surged 8631 bps in 2025.
- A 5-year view of Operating Margin shows it stood at 2.06% in 2022, then soared by 787 bps to 18.3% in 2023, then slipped by 28 bps to 13.19% in 2024, then plunged by 91 bps to 1.19% in 2025, then soared by 227 bps to 3.89% in 2026.
- The last three Operating Margin figures came in at 3.89% (Q1 2026), 1.19% (Q4 2025), and 3.54% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 16.37% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 36.83% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 41.69% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 20.77% |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 23.74% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 22.39% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -122.23% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 21.55% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -12.88% |
| 10 | Pacira BioSciences | 935.46 Mn | 733.28 Mn | 140.96 Mn | 3.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.89% |
| Dec 31, 2025 | 1.19% |
| Sep 30, 2025 | 3.54% |
| Jun 30, 2025 | 4.69% |
| Mar 31, 2025 | 1.18% |
| Dec 31, 2024 | 13.19% |
| Sep 30, 2024 | -82.77% |
| Jun 30, 2024 | 15.86% |
| Mar 31, 2024 | 7.91% |
| Dec 31, 2023 | 18.30% |
| Sep 30, 2023 | 10.81% |
| Jun 30, 2023 | 23.53% |
| Mar 31, 2023 | -1.93% |
| Dec 31, 2022 | 2.06% |
| Sep 30, 2022 | 12.71% |
| Jun 30, 2022 | 18.44% |
| Mar 31, 2022 | 11.01% |
| Dec 31, 2021 | 2.65% |
| Sep 30, 2021 | 24.61% |
| Jun 30, 2021 | 25.70% |